Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;13:955841. doi: 10.3389/fimmu.2022.955841

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Qin, Wang, Huang, Huang and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The clinical significance of PRSS23 overexpression was analyzed in the GC cohort from TCGA. (A) Differences in the immunostaining of PRSS23 between normal tissues and cancerous tissues in GC. (B, C) PRSS23 was overexpressed in cancerous tissues in the GSE54129 and TCGA_STAD cohort. (D) Differences in PRSS23 expression between intestinal and diffuse tissues of GC. (E) PRSS23 expression in GC tissues with different differentiation stages. (F–H) PRSS23 expression level in different TNM-stages of GC tissues. (I) PRSS23 was lowly expressed in GC patients with radiation therapy. (J, K): PRSS23 overexpression predicted shorter overall survival time and disease-free survival time in GC. **, P < 0.01, ***, P < 0.001.